The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate.
about
Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronicGeographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain.Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzaePulmonary damage and bacterial load in assessment of the efficacy of simulated human treatment-like amoxicillin (2,000 milligrams) therapy of experimental pneumococcal pneumonia caused by strains for which amoxicillin MICs differ.Formulation, characterization and physicochemical evaluation of amoxicillin effervescent tablets.Carisbamate acutely suppresses spasms in a rat model of symptomatic infantile spasmsAmoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia.Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC.Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles.Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatmeEffects of amoxicillin subinhibitory concentrations on the cross-protection developed by pneumococcal antibodies in mouse sepsis caused by an amoxicillin-resistant serotype 6B Streptococcus pneumoniae strain.Genetic relatedness of recently collected Spanish respiratory tract Streptococcus pneumoniae isolates with reduced susceptibility to amoxicillin.Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model.influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strainHighly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis.The current state of antibacterial research.High-dose versus standard-dose amoxicillin/clavulanate for clinically-diagnosed acute bacterial sinusitis: A randomized clinical trial.Comparison of adherence between twice- and thrice-daily regimens of oral amoxicillin/clavulanic acid
P2860
Q33556653-0ABB815E-93CA-41B7-ACA4-BAB529D6DBB2Q33770121-B3CA02C8-FB11-4550-BFC7-9D0660A68A0AQ33856741-57750F8F-9AFF-4696-A0CE-A2CDEE63AD43Q33857395-EE621ECF-641F-4458-85EE-28C0C041573BQ34447742-8BEE8978-047D-47BD-A605-3F84F85BD56FQ35204540-4B02AC69-42E6-4EC3-AB48-F3B25B375D53Q35548203-D31D12B7-7FDF-4A34-BFBB-CB0AA8A59977Q35964560-5421B683-29A0-46D6-8391-0A652EF60435Q36162353-9B9D465E-9C05-421F-A504-FD7CF9C4B0C5Q37489324-90E48F3B-0A22-44C5-A562-DA1FCE18889FQ37598755-10309C09-1FB3-47F8-B786-554F5C723219Q40130557-BB349A07-BC02-41DC-9032-E4D8BDDCF887Q40968324-4299FB49-883C-457C-AA92-89106A686BE8Q42012067-5065F88B-63B1-4280-8FE6-1B3D386D4DDCQ50026462-F8C0A04D-779B-4B34-88FD-9957FB81DD85Q53882875-493FE1C9-BAD9-4853-92EA-62FE688CA220Q55086331-83AB581E-3BD8-4695-9B97-A84EC3FE2B94Q57777837-7A0539BA-9CDC-424B-9118-43387DF4823E
P2860
The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
The clinical pharmacokinetics ...... on of amoxicillin/clavulanate.
@en
The clinical pharmacokinetics ...... on of amoxicillin/clavulanate.
@nl
type
label
The clinical pharmacokinetics ...... on of amoxicillin/clavulanate.
@en
The clinical pharmacokinetics ...... on of amoxicillin/clavulanate.
@nl
prefLabel
The clinical pharmacokinetics ...... on of amoxicillin/clavulanate.
@en
The clinical pharmacokinetics ...... on of amoxicillin/clavulanate.
@nl
P2093
P1476
The clinical pharmacokinetics ...... on of amoxicillin/clavulanate.
@en
P2093
McDonagh M
P304
P356
10.1016/S0149-2918(01)80061-8
P577
2001-04-01T00:00:00Z